SG11201509194SA - Radiomitigating pharmaceutical formulations - Google Patents
Radiomitigating pharmaceutical formulationsInfo
- Publication number
- SG11201509194SA SG11201509194SA SG11201509194SA SG11201509194SA SG11201509194SA SG 11201509194S A SG11201509194S A SG 11201509194SA SG 11201509194S A SG11201509194S A SG 11201509194SA SG 11201509194S A SG11201509194S A SG 11201509194SA SG 11201509194S A SG11201509194S A SG 11201509194SA
- Authority
- SG
- Singapore
- Prior art keywords
- radiomitigating
- pharmaceutical formulations
- formulations
- pharmaceutical
- radiomitigating pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361820447P | 2013-05-07 | 2013-05-07 | |
| PCT/US2014/037110 WO2014182789A2 (en) | 2013-05-07 | 2014-05-07 | Radiomitigating pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509194SA true SG11201509194SA (en) | 2015-12-30 |
Family
ID=51867859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509194SA SG11201509194SA (en) | 2013-05-07 | 2014-05-07 | Radiomitigating pharmaceutical formulations |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9783515B2 (en) |
| EP (1) | EP2994457B1 (en) |
| JP (1) | JP2016523830A (en) |
| KR (1) | KR20160005356A (en) |
| CN (1) | CN105579439B (en) |
| AU (1) | AU2014262764B2 (en) |
| CA (1) | CA2911902A1 (en) |
| ES (1) | ES2860949T3 (en) |
| IL (1) | IL242493B (en) |
| SG (1) | SG11201509194SA (en) |
| WO (1) | WO2014182789A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130203722A1 (en) | 2006-09-26 | 2013-08-08 | Rhonda R. Voskuhl | Estriol therapy for autoimmune and neurodegenerative disease and disorders |
| CA2911902A1 (en) * | 2013-05-07 | 2014-11-13 | The Regents Of The University Of California | Radiomitigating pharmaceutical formulations |
| WO2017156222A1 (en) * | 2016-03-09 | 2017-09-14 | The Regents Of The University Of California | Radiomitigating compounds, compositions and methods related thereto |
| AU2017342551B2 (en) * | 2016-10-16 | 2022-10-20 | BCN Biosciences L.L.C. | Methods of treatment and pharmaceutical compositions using BCN057 or BCN512 |
| WO2019032739A1 (en) * | 2017-08-08 | 2019-02-14 | BCN Biosciences L.L.C. | Methods of treating radiation induced gastrointestinal syndrome (rigs) and related disease states using compound 512 |
| WO2023122723A1 (en) | 2021-12-23 | 2023-06-29 | The Broad Institute, Inc. | Panels and methods for diagnosing and treating lung cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4159331A (en) | 1978-05-05 | 1979-06-26 | The Upjohn Company | Antihypertensive 4-aminoquinolines |
| ES2267873T3 (en) | 1997-10-27 | 2007-03-16 | Agouron Pharmaceuticals, Inc. | DERIVATIVES OF 4-AMINOTIAZOL, ITS PREPARATION AND USE AS INHIBITORS OF CYCLINE DEPENDENT KINASES. |
| US6407120B1 (en) * | 1999-02-18 | 2002-06-18 | Pfizer Inc. | Neuropeptide Y antagonists |
| IT1313594B1 (en) * | 1999-08-03 | 2002-09-09 | Novuspharma Spa | BISPLATIN ORAL ACTIVITIES. |
| US7223751B2 (en) * | 2001-04-26 | 2007-05-29 | Kolon Ind. Inc. | Sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same |
| DK1689706T3 (en) * | 2003-11-14 | 2017-04-03 | Temple Univ - Of The Commonwealth System Of Higher Education | Alpha, beta-unsaturated sulfoxides for the treatment of proliferative disorders |
| JP2005232101A (en) * | 2004-02-20 | 2005-09-02 | Rikogaku Shinkokai | Celecoxibaminoalkyl derivative |
| US7345043B2 (en) | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
| MY140912A (en) | 2004-07-26 | 2010-01-29 | Du Pont | Mixtures of anthranilamide invertebrate pest control agents |
| US7615570B2 (en) * | 2004-12-13 | 2009-11-10 | Abbott Laboratories | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| WO2007029078A2 (en) * | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Succinimide and glutarimide derivatives as adrenergic receptor antagonists |
| JP2009539880A (en) | 2006-06-09 | 2009-11-19 | アイコス コーポレイション | Substituted phenylacetic acid as a DP-2 antagonist |
| US20080207621A1 (en) | 2006-09-28 | 2008-08-28 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| CA2729766A1 (en) | 2008-07-01 | 2010-01-07 | Zacharon Pharmaceuticals, Inc. | Heparan sulfate inhibitors |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| EP2411529A4 (en) | 2009-03-27 | 2012-09-19 | Zacharon Pharmaceuticals Inc | N-linked glycan biosynthesis modulators |
| US8546397B2 (en) * | 2010-12-20 | 2013-10-01 | The Ohio State University Research Foundation | DNA methylation inhibitors |
| US9217000B2 (en) * | 2011-02-18 | 2015-12-22 | Univerisyt of Pittsburgh—of the Commonwealth System of Higher Education | Targeted nitroxide agents |
| CA2911902A1 (en) * | 2013-05-07 | 2014-11-13 | The Regents Of The University Of California | Radiomitigating pharmaceutical formulations |
-
2014
- 2014-05-07 CA CA2911902A patent/CA2911902A1/en not_active Abandoned
- 2014-05-07 US US14/889,719 patent/US9783515B2/en active Active
- 2014-05-07 EP EP14794084.5A patent/EP2994457B1/en active Active
- 2014-05-07 ES ES14794084T patent/ES2860949T3/en active Active
- 2014-05-07 SG SG11201509194SA patent/SG11201509194SA/en unknown
- 2014-05-07 CN CN201480038705.0A patent/CN105579439B/en active Active
- 2014-05-07 KR KR1020157034769A patent/KR20160005356A/en not_active Application Discontinuation
- 2014-05-07 JP JP2016513039A patent/JP2016523830A/en active Pending
- 2014-05-07 AU AU2014262764A patent/AU2014262764B2/en active Active
- 2014-05-07 WO PCT/US2014/037110 patent/WO2014182789A2/en active Application Filing
-
2015
- 2015-11-08 IL IL242493A patent/IL242493B/en active IP Right Grant
-
2016
- 2016-04-08 US US15/094,192 patent/US9840483B2/en active Active
-
2017
- 2017-11-14 US US15/812,321 patent/US20180162827A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105579439B (en) | 2018-10-19 |
| AU2014262764A1 (en) | 2015-12-17 |
| IL242493B (en) | 2020-08-31 |
| JP2016523830A (en) | 2016-08-12 |
| US9783515B2 (en) | 2017-10-10 |
| CN105579439A (en) | 2016-05-11 |
| US20160221976A1 (en) | 2016-08-04 |
| WO2014182789A2 (en) | 2014-11-13 |
| EP2994457B1 (en) | 2021-01-06 |
| EP2994457A4 (en) | 2016-09-28 |
| US9840483B2 (en) | 2017-12-12 |
| CA2911902A1 (en) | 2014-11-13 |
| US20160090369A1 (en) | 2016-03-31 |
| ES2860949T3 (en) | 2021-10-05 |
| AU2014262764B2 (en) | 2018-11-15 |
| WO2014182789A3 (en) | 2014-12-11 |
| US20180162827A1 (en) | 2018-06-14 |
| IL242493A0 (en) | 2016-02-01 |
| EP2994457A2 (en) | 2016-03-16 |
| KR20160005356A (en) | 2016-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288961A (en) | Pharmaceutical compositions | |
| SI3030262T1 (en) | Combined pharmaceutical composition | |
| EP3065716C0 (en) | Formulations | |
| PL2943181T3 (en) | Pharmaceutical compositions | |
| ZA201408333B (en) | Pharmaceutical compositions | |
| GB201319792D0 (en) | Formulations | |
| HK1214951A1 (en) | Ophthalimic formulations | |
| SG11201509194SA (en) | Radiomitigating pharmaceutical formulations | |
| SG11201601477VA (en) | Pharmaceutical composition | |
| ZA201600027B (en) | Pharmaceutical preparation | |
| HRP20171888T1 (en) | Pharmaceutical compositions | |
| HUP1300496A2 (en) | Stable pharmaceutical composition | |
| HK1220143A1 (en) | Pharmaceutical composition | |
| GB201304699D0 (en) | Pharmaceutical compositions | |
| IL244316A0 (en) | Novel drug formulation | |
| ZA201506465B (en) | Pharmaceutical preparation | |
| GB201321497D0 (en) | Pharmaceutical compositions | |
| GB201312851D0 (en) | Pharmaceutical compositions | |
| GB201316662D0 (en) | Pharmaceutical Combination | |
| GB201301723D0 (en) | Pharmaceutical combinations |